Patents by Inventor David Rodney Ungar

David Rodney Ungar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage regimes for the administration of an anti-CD19 ADC
    Patent number: 11938192
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 26, 2024
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SA
    Inventors: Jay Marshall Feingold, David Rodney Ungar
  • DOSAGE REGIME
    Publication number: 20230106885
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
    Type: Application
    Filed: October 5, 2022
    Publication date: April 6, 2023
    Inventors: Jay Marshall FEINGOLD, David Rodney UNGAR
  • DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC
    Publication number: 20220280651
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
    Type: Application
    Filed: March 18, 2022
    Publication date: September 8, 2022
    Inventors: Jay Marshall Feingold, David Rodney Ungar
  • Dosage regimes for the administration of an anti-CD19 ADC
    Patent number: 11318211
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 3, 2022
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Jay Marshall Feingold, David Rodney Ungar
  • DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC
    Publication number: 20200171164
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
    Type: Application
    Filed: June 14, 2018
    Publication date: June 4, 2020
    Inventors: Jay Marshall Feingold, David Rodney Ungar